Cryptolepis Sanguinolenta (Cryptolepis sanguinolenta): Benefits, Dosage, Safety & Evidence

Frequently asked questions

How does Cryptolepis sanguinolenta work against malaria?

Cryptolepis sanguinolenta contains indoloquinoline alkaloids, primarily cryptolepine, which intercalate into parasite DNA and inhibit replication in Plasmodium species. These compounds disrupt DNA synthesis and induce oxidative stress in malaria parasites. The herb also demonstrates broad-spectrum antimicrobial activity against bacteria and fungi. While laboratory studies confirm antimalarial mechanisms, human clinical trials remain limited (Evidence Level C). Traditional use in West Africa spans generations as a primary malaria treatment.

Can Cryptolepis sanguinolenta be taken with antimalarial drugs or other medications?

Cryptolepis sanguinolenta may interact with antihypertensive medications due to its blood pressure-lowering effects, potentially causing additive hypotension. Patients taking cardiac medications should avoid this herb entirely. No well-documented interactions with conventional antimalarial drugs have been established, but concurrent use warrants medical supervision. The herb affects cardiac function at therapeutic doses, making it contraindicated for those with heart conditions or on heart medications (Evidence Level C).

What is the recommended dosage of Cryptolepis sanguinolenta for malaria?

Traditional adult dosage involves drinking 200ml of plant decoction three times daily for 5 consecutive days. Standardized extract preparations typically recommend 200mg daily. Preparation methods and alkaloid concentrations vary significantly between sources, making product-specific instructions essential. This herb is contraindicated for children under 12 years old. Due to potential cardiac effects and limited clinical standardization, consultation with a qualified herbalist or healthcare provider is strongly recommended before use (Evidence Level C, Traditional).

Is Cryptolepis sanguinolenta safe during pregnancy and breastfeeding?

Cryptolepis sanguinolenta is contraindicated during pregnancy and breastfeeding. The alkaloid cryptolepine may cross the placental barrier and potentially harm fetal development. Traditional knowledge and available pharmacological evidence classify this herb as unsafe for pregnant individuals (Evidence Level C). Women who are pregnant, planning pregnancy, or breastfeeding should avoid Cryptolepis entirely and consult healthcare providers for safer antimalarial alternatives.

What are the side effects of Cryptolepis sanguinolenta?

Common side effects include nausea and gastrointestinal discomfort. More serious concerns involve dose-dependent cardiac effects, including potential arrhythmias and hypotension at higher doses. The therapeutic window between effective and toxic doses appears narrow, particularly regarding cardiovascular effects. Traditional preparation methods may reduce some adverse effects compared to concentrated extracts. Anyone experiencing irregular heartbeat, dizziness, or severe nausea should discontinue use immediately and seek medical attention (Evidence Level C, Traditional).

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 30 PubMed articles · model: gemma4:31b

Summary

Cryptolepis sanguinolenta is a West African medicinal shrub primarily used for treating malaria and other microbial infections [PMID: 29750083, 38840271].

Background

Cryptolepis sanguinolenta (Lindl.) Schlt. is a scrambling thin-stemmed shrub native to Africa [PMID: 29750083]. It is often referred to as Ghanaian quinine or yellow dye root [PMID: 37636997].

Traditional uses

In West Africa, it is traditionally employed to treat malaria, diarrhea, and respiratory conditions [PMID: 29750083]. It is also used in folklore medicine for the management of diabetes mellitus [PMID: 22701855].

Active compounds

The main alkaloid is cryptolepine [PMID: 7853867]. Other identified compounds include neocryptolepine, isocryptolepine [PMID: 20491639], quindoline, hydroxycryptolepine [PMID: 8720383], and novel indoloquinoline alkaloid glycosides Cryptospirosanguine A and B [PMID: 37427973].

Mechanism of action

Cryptolepine acts as a cytotoxic DNA intercalator and inhibits DNA synthesis and topoisomerase II [PMID: 36251044, 12441369]. It also demonstrates antimuscarinic activity by antagonizing M1, M2, and M3 receptors [PMID: 1484884].

Clinical evidence

Evidence BAcute uncomplicated falciparum malaria

A tea-bag formulation of the root cleared P. falciparum parasitaemia in 50% of patients by 72 hours and 100% by Day 7; symptoms of fever, chills, nausea, and vomiting cleared by Day 3 [PMID: 21326984]

Evidence DDiabetes mellitus (rat model)

Stem extracts significantly decreased glucose transport and absorption, and reduced plasma glucose, total cholesterol, triglycerides, and LDL cholesterol [PMID: 22701855]

Evidence DMale fertility (rat model)

Leaf ethanolic extract led to significant testosterone suppression, increased luteinizing hormone (LH), and decreased sperm count [PMID: 22870014]

Evidence DBacterial infections (in vitro)

Root extracts showed activity against Campylobacter jejuni, Campylobacter coli, and Vibrio cholerae [PMID: 7853867], as well as Staphylococcus aureus and Escherichia coli [PMID: 8778508].

Evidence DBabesia duncani (in vitro)

The herb and its compound cryptolepine demonstrated inhibitory activity against B. duncani in a hamster erythrocyte model [PMID: 33763384]

Safety & adverse effects

Cryptolepine and aqueous root extracts are potently cytotoxic to mammalian cells and can cause a dose- and time-dependent reduction in viability of V79 cells [PMID: 12441369, 24391229]. Indoloquinoline alkaloids are noted for associated cellular toxicity, which is a drawback for preclinical development [PMID: 38840271].

Dosage & administration

In one clinical trial for malaria, patients were given one root tea-bag three times a day (morning, noon, and night) for five days [PMID: 21326984]. No PubMed data available. Consult a healthcare provider.

Evidence summary

Evidence is primarily based on in vitro studies (D) and a small open clinical trial (B). While potent antimicrobial and antimalarial activities are documented, significant cellular toxicity is a noted concern.

PubMed sources

1.PMID: 38770341 (2024) — Increasing the planting density of Cryptolepis sanguinolenta (Lindl.) Schlt increased root biomass and cryptolepine yield. · Heliyon
2.PMID: 37344802 (2023) — Antimicrobial, antioxidant activities, and total phenolic contents of Pycnanthus angolensis Sap and Cryptolepis sanguinolenta root extracts. · BMC complementary medicine and therapies
3.PMID: 7853867 (1994) — Cryptolepis sanguinolenta activity against diarrhoeal bacteria. · Journal of ethnopharmacology
4.PMID: 35009125 (2022) — Mineral Fertilization Influences the Growth, Cryptolepine Yield, and Bioefficacy of Cryptolepis sanguinolenta (Lindl.) Schlt. · Plants (Basel, Switzerland)
5.PMID: 29750083 (2017) — Phytochemical and Pharmacological Review of Cryptolepis sanguinolenta (Lindl.) Schlechter.

Cryptolepis Sanguinolenta

Sources & Citations

Calculate a safe dose of Cryptolepis Sanguinolenta